Molecular Brain Imaging in the Multimodality Era
暂无分享,去创建一个
[1] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[2] M. Albert,et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[3] J. Detre,et al. Potentials and Challenges for Arterial Spin Labeling in Pharmacological Magnetic Resonance Imaging , 2011, Journal of Pharmacology and Experimental Therapeutics.
[4] Nick C Fox,et al. Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.
[5] Ronald Boellaard,et al. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner , 2007, Physics in medicine and biology.
[6] M. Greicius,et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.
[7] K Fetterly,et al. Positron emission tomography within a magnetic field using photomultiplier tubes and lightguides. , 1995, Physics in medicine and biology.
[8] R. Treede,et al. Human brain mechanisms of pain perception and regulation in health and disease , 2005, European journal of pain.
[9] W C Eckelman,et al. Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[10] Nick C Fox,et al. The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.
[11] Michael V. Green,et al. PET imaging of brain with the β-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[12] Norbert Schuff,et al. A non-parametric approach for co-analysis of multi-modal brain imaging data: Application to Alzheimer's disease , 2006, NeuroImage.
[13] Nick C Fox,et al. The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .
[14] Paul M. Thompson,et al. Staging Alzheimer's disease progression with multimodality neuroimaging , 2011, Progress in Neurobiology.
[15] D. Paik,et al. Noninvasive detection of therapeutic cytolytic T cells with 18F–FHBG PET in a patient with glioma , 2009, Nature Clinical Practice Oncology.
[16] Habib Zaidi,et al. Preclinical Multimodality Imaging in Vivo. , 2008, PET clinics.
[17] Anders M. Dale,et al. Diffuse optical imaging of brain activation: approaches to optimizing image sensitivity, resolution, and accuracy , 2004, NeuroImage.
[18] André Luxen,et al. PET radiotracers for molecular imaging in the brain: Past, present and future , 2012, NeuroImage.
[19] G. Alexander,et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.
[20] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] M. Weiner,et al. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia , 2011, Trends in Neurosciences.
[22] Richard G. Wise,et al. Combining fMRI with a Pharmacokinetic Model to Determine Which Brain Areas Activated by Painful Stimulation Are Specifically Modulated by Remifentanil , 2002, NeuroImage.
[23] L. Shah,et al. Functional magnetic resonance imaging. , 2010, Seminars in roentgenology.
[24] Tianzi Jiang,et al. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: Evidence from resting state fMRI , 2006, NeuroImage.
[25] R H Huesman,et al. Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type: Positron Emission Tomography with [1818] Fluorodeoxyglucose , 1983, Journal of computer assisted tomography.
[26] A. Drzezga,et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] R. Buckner. Memory and Executive Function in Aging and AD Multiple Factors that Cause Decline and Reserve Factors that Compensate , 2004, Neuron.
[28] Francis Eustache,et al. The Default Mode Network in Healthy Aging and Alzheimer's Disease , 2011, International journal of Alzheimer's disease.
[29] K Herholz,et al. Positron emission tomography imaging in dementia. , 2007, The British journal of radiology.
[30] M. Laruelle. Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] Paul M. Thompson,et al. Mapping hippocampal and ventricular change in Alzheimer disease , 2004, NeuroImage.
[32] A. Petiet,et al. In Vivo Imaging Biomarkers in Mouse Models of Alzheimer's Disease: Are We Lost in Translation or Breaking Through? , 2010, International journal of Alzheimer's disease.
[33] F. Beekman,et al. High-resolution tomography of positron emitters with clustered pinhole SPECT , 2010, Physics in medicine and biology.
[34] S. DeKosky,et al. Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.
[35] Abraham Z. Snyder,et al. A default mode of brain function: A brief history of an evolving idea , 2007, NeuroImage.
[36] J. Lanciego,et al. Adeno-associated virus liver transduction efficiency measured by in vivo [18F]FHBG positron emission tomography imaging in rodents and nonhuman primates. , 2011, Human gene therapy.
[37] Anthony Randal McIntosh,et al. Partial Least Squares (PLS) methods for neuroimaging: A tutorial and review , 2011, NeuroImage.
[38] E T Bullmore,et al. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans , 2011, Molecular Psychiatry.
[39] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[40] Jeff H Duyn,et al. Novel frontiers in ultra-structural and molecular MRI of the brain. , 2011, Current opinion in neurology.
[41] P. Barker,et al. MR spectroscopy and spectroscopic imaging of the brain. , 2011, Methods in molecular biology.
[42] R. Buxton. Neuroenergetics Review Article , 2022 .
[43] N. Lassen,et al. Tracer kinetic methods in medical physiology , 1979 .
[44] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[45] A. Verma,et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study , 2008 .
[46] Benjamin J. Shannon,et al. Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.
[47] M. Albert,et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD , 2005, Neurology.
[48] W. Thies,et al. 2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.
[49] Heinrich Lanfermann,et al. Multimodality Assessment of Brain Tumors and Tumor Recurrence , 2011, The Journal of Nuclear Medicine.
[50] Jeffrey A. James,et al. Amyloid imaging in mild cognitive impairment subtypes , 2009, Annals of neurology.
[51] Brian J Bacskai,et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[52] A. Fagan,et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.
[53] B. Hyman,et al. Imaging amyloid-beta deposits in vivo. , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[54] Sungho Tak,et al. NIRS-SPM: statistical parametric mapping for near infrared spectroscopy , 2008, SPIE BiOS.
[55] Yul-Wan Sung,et al. Functional magnetic resonance imaging , 2004, Scholarpedia.
[56] W. Jagust,et al. Clinical Studies of Cerebral Blood Flow in Alzheimer's Disease , 1997, Annals of the New York Academy of Sciences.
[57] K. Blennow,et al. Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease , 2007, Annals of the New York Academy of Sciences.
[58] Karl J. Friston,et al. Stochastic Designs in Event-Related fMRI , 1999, NeuroImage.
[59] Mark Slifstein,et al. Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [11C] P943: A positron emission tomography study in Papio anubis , 2011, Synapse.
[60] Mark E. Schmidt,et al. The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.
[61] D. Townsend. Multimodality imaging of structure and function , 2008, Physics in medicine and biology.
[62] [A simulation study to evaluate the statistical noise and spatial resolution in image reconstruction of emission computed tomography--with respect to the optimization of the filter function in the convolution integral]. , 1986, Radioisotopes.
[63] Christer Halldin,et al. Confirmation of Fenfluramine Effect on 5-HT1B Receptor Binding of [11C]AZ10419369 using an Equilibrium Approach , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[64] D. Sharp,et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. , 2012, The British journal of psychiatry : the journal of mental science.
[65] Paul Edison,et al. Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.
[66] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[67] R. Petersen,et al. Aging, Memory, and Mild Cognitive Impairment , 1997, International Psychogeriatrics.
[68] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[69] David A Boas,et al. Direct estimation of evoked hemoglobin changes by multimodality fusion imaging. , 2008, Journal of biomedical optics.
[70] R. Blasberg. Imaging Gene Expression and Endogenous Molecular Processes: Molecular Imaging , 2002, Journal of Cerebral Blood Flow and Metabolism.
[71] K Wienhard,et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas , 2001, The Lancet.
[72] R. Gobetto,et al. Hyperpolarized agents for advanced MRI investigations. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[73] Tetsuya Suhara,et al. Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.
[74] B. Hyman,et al. Imaging Amyloid-β Deposits In Vivo , 2002 .
[75] P. Thompson,et al. Diffusion imaging, white matter, and psychopathology. , 2011, Annual review of clinical psychology.
[76] Costas Balas,et al. Review of biomedical optical imaging—a powerful, non-invasive, non-ionizing technology for improving in vivo diagnosis , 2009 .
[77] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[78] Satoshi Minoshima,et al. Posterior cingulate cortex in Alzheimer's disease , 1994, The Lancet.
[79] C. Jack,et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD , 2000, Neurology.
[80] David A Mankoff,et al. A definition of molecular imaging. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[81] S. Cherry,et al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging , 2008, Proceedings of the National Academy of Sciences of the United States of America.
[82] D. Schacter,et al. The Brain's Default Network , 2008, Annals of the New York Academy of Sciences.
[83] J S Fowler,et al. Amphetamine induced decreases in (18F)‐N‐methylspiroperidol binding in the baboon brain using positron emission tomography (PET) , 1991, Synapse.
[84] Randy L. Gollub,et al. A combined [11C]diprenorphine PET study and fMRI study of acupuncture analgesia , 2008, Behavioural Brain Research.
[85] B. Hyman,et al. Transgenic models of Alzheimer’s disease: Learning from animals , 2005, NeuroRX.
[86] M. Bobinski,et al. Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease , 1997, Neurobiology of Aging.
[87] C. Jack,et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.
[88] Mrinmoy De,et al. Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications. , 2011, Advanced drug delivery reviews.
[89] B. Pichler,et al. Pre-clinical PET/MR: technological advances and new perspectives in biomedical research , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[90] P. Matthews,et al. Neuroimaging: Applications of fMRI in translational medicine and clinical practice , 2006, Nature Reviews Neuroscience.
[91] Claude Comtat,et al. Assessment of 11C-PE2I Binding to the Neuronal Dopamine Transporter in Humans with the High-Spatial-Resolution PET Scanner HRRT , 2007, Journal of Nuclear Medicine.
[92] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[93] Ramon Casanova,et al. Biological parametric mapping: A statistical toolbox for multimodality brain image analysis , 2007, NeuroImage.
[94] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[95] E. Reiman,et al. Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.
[96] R Weissleder,et al. Continuous assessment of perfusion by tagging including volume and water extraction (CAPTIVE): A steady‐state contrast agent technique for measuring blood flow, relative blood volume fraction, and the water extraction fraction , 1998, Magnetic resonance in medicine.
[97] Keith A. Johnson,et al. Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia , 2009, Neuron.
[98] K. P. Lindsey,et al. Partitioning of Physiological Noise Signals in the Brain with Concurrent Near-Infrared Spectroscopy and fMRI , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[99] Jeffrey A. Fessler,et al. Advanced three-dimensional tailored RF pulse for signal recovery in T-weighted functional MRI , 2006 .
[100] E. Karageorgiou,et al. NEUROIMAGING IN DEMENTIA , 2010, Continuum.
[101] Vinod Menon,et al. Functional connectivity in the resting brain: A network analysis of the default mode hypothesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[102] C. Claussen,et al. Simultaneous Mr/pet Imaging of the Human Brain: Feasibility Study 1 , 2022 .
[103] Gian Domenico Iannetti,et al. Regions of interest analysis in pharmacological fMRI: How do the definition criteria influence the inferred result? , 2008, NeuroImage.
[104] H. Engler,et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.
[105] Mark Slifstein,et al. Striatal and extrastriatal dopamine release measured with PET and [18F] fallypride , 2010, Synapse.
[106] W. Klunk,et al. Impact of amyloid imaging on drug development in Alzheimer's disease. , 2007, Nuclear medicine and biology.
[107] S. Thibodeau,et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.
[108] C. Jack,et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.
[109] G. Alexander,et al. Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[110] Douglas C Noll,et al. Advanced three‐dimensional tailored RF pulse for signal recovery in T2*‐weighted functional magnetic resonance imaging , 2006, Magnetic resonance in medicine.
[111] John A. Detre,et al. Clinical neuroimaging using arterial spin-labeled perfusion magnetic resonance imaging , 2007, Neurotherapeutics.
[112] Nick C Fox,et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.
[113] K-J Langen,et al. High resolution BrainPET combined with simultaneous MRI , 2011, Nuklearmedizin.
[114] Ryan Chamberlain,et al. Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease. , 2011, Current medical imaging reviews.
[115] J. Streffer,et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy , 2004, Molecular Psychiatry.
[116] Yannic Waerzeggers,et al. Mouse models in neurological disorders: applications of non-invasive imaging. , 2010, Biochimica et biophysica acta.
[117] Costin Tanase,et al. Loss of cell ion homeostasis and cell viability in the brain: what sodium MRI can tell us. , 2005, Current topics in developmental biology.
[118] A. Goate,et al. Molecular genetics of Alzheimer's disease. , 1993, Archives of neurology.
[119] Bedda L. Rosario,et al. Basal Cerebral Metabolism May Modulate the Cognitive Effects of Aβ in Mild Cognitive Impairment: An Example of Brain Reserve , 2009, The Journal of Neuroscience.
[120] B R Rosen,et al. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: Correlation with PET, microdialysis, and behavioral data , 1997, Magnetic resonance in medicine.
[121] W. Klunk,et al. Update on amyloid imaging: From healthy aging to Alzheimer’s disease , 2009, Current neurology and neuroscience reports.
[122] S. Gambhir,et al. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.
[123] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[124] G. Delso,et al. Performance Measurements of the Siemens mMR Integrated Whole-Body PET/MR Scanner , 2011, The Journal of Nuclear Medicine.
[125] Joel S. Karp,et al. Concurrent CBF and CMRGlc changes during human brain activation by combined fMRI–PET scanning , 2005, NeuroImage.